Malta - English - Medicines Authority

dr. friedrich eberth arzneimittel gmbh am bahnhof 2, ursensollen 92289, germany - cefuroxime sodium - powder for solution for infusion or injection - cefuroxime sodium 750 mg - antibacterials for systemic use

Malta - English - Medicines Authority

dr. friedrich eberth arzneimittel gmbh am bahnhof 2, ursensollen 92289, germany - cefuroxime sodium - powder for solution for infusion or injection - cefuroxime sodium 1500 mg - antibacterials for systemic use

Israel - English - Ministry of Health

pharmalogic ltd - cefuroxime as sodium - powder for solution for inj/inf - cefuroxime as sodium 750 mg/vial - cefuroxime - cefuroxime - infections caused by susceptible microorganisms, prophylaxis against post operative infections in a variety of operations.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern xp ip pty ltd - cefuroxime sodium, quantity: 1577.7 mg (equivalent: cefuroxime, qty 1500 mg) - injection, powder for - excipient ingredients: - cefuroxime sxp is indicated in adults and children of 40 kg or greater in weight for the prevention of infections associated with certain surgical procedures of the gastrointestinal (including oesophageal), orthopaedic, cardiovascular and gynaecological systems (including caesarean section) (see section 4.4: special warnings and precautions for use and section 5.2: pharmacokinetic properties).,in the prevention of infections in which it is very likely that anaerobic organisms will be encountered, cefuroxime should be administered with additional appropriate antibacterial agents such as metronidazole.,consideration should be given to official guidance on the appropriate use of antibacterial agents, as antibiotic prophylaxis is not required in all gastrointestinal, orthopaedic, cardiovascular and gynaecological procedures or surgeries.,for patients with specific cardiac conditions which predispose them to endocarditis who are undergoing abdominal surgery for which surgical antibiotic prophylaxis is indicated, the prophylaxis regimen should additionally include an antibiotic active against enterococci.,for patients undergoing orthopedic or cardiovascular surgery known to be, or at risk of being, colonised or infected with methicillin-resistant s. aureus (mrsa), add an antibiotic with activity against mrsa, such as vancomycin.,cefuroxime sxp is not indicated in children less than 40 kg in weight.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern xp ip pty ltd - cefuroxime sodium, quantity: 788.9 mg (equivalent: cefuroxime, qty 750 mg) - injection, powder for - excipient ingredients: - cefuroxime sxp is indicated in adults and children of 40 kg or greater in weight for the prevention of infections associated with certain surgical procedures of the gastrointestinal (including oesophageal), orthopaedic, cardiovascular and gynaecological systems (including caesarean section) (see section 4.4: special warnings and precautions for use and section 5.2: pharmacokinetic properties).,in the prevention of infections in which it is very likely that anaerobic organisms will be encountered, cefuroxime should be administered with additional appropriate antibacterial agents such as metronidazole.,consideration should be given to official guidance on the appropriate use of antibacterial agents, as antibiotic prophylaxis is not required in all gastrointestinal, orthopaedic, cardiovascular and gynaecological procedures or surgeries.,for patients with specific cardiac conditions which predispose them to endocarditis who are undergoing abdominal surgery for which surgical antibiotic prophylaxis is indicated, the prophylaxis regimen should additionally include an antibiotic active against enterococci.,for patients undergoing orthopedic or cardiovascular surgery known to be, or at risk of being, colonised or infected with methicillin-resistant s. aureus (mrsa), add an antibiotic with activity against mrsa, such as vancomycin.,cefuroxime sxp is not indicated in children less than 40 kg in weight.

Ireland - English - HPRA (Health Products Regulatory Authority)

syri limited, t/a thame laboratories - furosemide - oral solution - 8 milligram(s)/millilitre - sulfonamides, plain; furosemide - high-ceiling diuretic sulfonamide - furosemide is indicated in all conditions requiring prompt diuresis in patients who are unable to take solid dose forms. indications include cardiac, pulmonary, hepatic and renal oedema, peripheral oedema due to mechanical obstruction or venous insufficiency and hypertension.

Ireland - English - HPRA (Health Products Regulatory Authority)

syri limited, t/a thame laboratories - furosemide - oral solution - 10 milligram(s)/millilitre - sulfonamides, plain; furosemide - high-ceiling diuretic sulfonamide - furosemide is indicated in all conditions requiring prompt diuresis in patients who are unable to take solid dose forms. indications include cardiac, pulmonary, hepatic and renal oedema, peripheral oedema due to mechanical obstruction or venous insufficiency and hypertension.

Ireland - English - HPRA (Health Products Regulatory Authority)

syri limited, t/a thame laboratories - furosemide - oral solution - 4 milligram(s)/millilitre - sulfonamides, plain; furosemide - high-ceiling diuretic sulfonamide - furosemide is indicated in all conditions requiring prompt diuresis in patients who are unable to take solid dose forms. indications include cardiac, pulmonary, hepatic and renal oedema, peripheral oedema due to mechanical obstruction or venous insufficiency and hypertension

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - furosemide, quantity: 50 mg - injection, solution - excipient ingredients: water for injections; hydrochloric acid; sodium hydroxide; sodium chloride - oedema: furosemide-baxter injection is indicated in adults, infants and children for the treatment of oedema associated with congestive heart failure, cirrhosis of the liver and renal disease including the nephrotic syndrome. frusemide is particularly useful when an agent with greater diuretic potential than that of those commonly employed is desired. parenteral therapy should be reserved for patients unable to take oral medication or for patients in emergency clinical situations. furosemide-baxter injection is also indicated as adjunctive therapy in acute pulmonary oedema and cerebral oedema where intense and rapid onset is desired. if gastrointestinal absorption is impaired or oral medication is not practical for any reason, frusemide is indicated by the intravenous route. parenteral use should be replaced with oral frusemide as soon as practical.

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - furosemide, quantity: 20 mg - injection, solution - excipient ingredients: sodium hydroxide; water for injections; sodium chloride; hydrochloric acid - oedema: furosemide-baxter injection is indicated in adults, infants and children for the treatment of oedema associated with congestive heart failure, cirrhosis of the liver and renal disease including the nephrotic syndrome. frusemide is particularly useful when an agent with greater diuretic potential than that of those commonly employed is desired. parenteral therapy should be reserved for patients unable to take oral medication or for patients in emergency clinical situations. furosemide-baxter injection is also indicated as adjunctive therapy in acute pulmonary oedema and cerebral oedema where intense and rapid onset is desired. if gastrointestinal absorption is impaired or oral medication is not practical for any reason, frusemide is indicated by the intravenous route. parenteral use should be replaced with oral frusemide as soon as practical.